PE20110207A1 - Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes - Google Patents

Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes

Info

Publication number
PE20110207A1
PE20110207A1 PE2011000019A PE2011000019A PE20110207A1 PE 20110207 A1 PE20110207 A1 PE 20110207A1 PE 2011000019 A PE2011000019 A PE 2011000019A PE 2011000019 A PE2011000019 A PE 2011000019A PE 20110207 A1 PE20110207 A1 PE 20110207A1
Authority
PE
Peru
Prior art keywords
methyl
methanocinoline
tetrahydrospiro
diaza
cyclopropane
Prior art date
Application number
PE2011000019A
Other languages
English (en)
Inventor
Jean Ackermann
Kurt Amrein
Bernd Kuhn
Alexander V Mayweg
Werner Neidhart
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41050326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110207(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20110207A1 publication Critical patent/PE20110207A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/28—Cinnolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE TETRAHIDROCINOLINA DE FORMULA (I) DONDE A ES CRaRb O -CH2-CH2-; R1 Y R2 SON H O ALQUILO C1-C8 LINEAL O RAMIFICADO; R3 ES ALQUILO C1-C8, CICLOALQUILO C3-C8, ARILO, ENTRE OTROS; Ra ES H O METILO; Rb ES H O METILO; Ra Y Rb JUNTO AL ATOMO DE CARBONO AL QUE ESTAN UNIDOS FORMAN UN CICLOPROPILO, CICLOBUTILO O CICLOPENTILO, CON LA CONDICION DE QUE SI Ra Y Rb SON H O METILO AL MISMO TIEMPO ENTONCES R3 ES (1-METIL-CICLOPROPIL)METILO. SON COMPUESTOS PREFERIDOS: (5'RS,8'SR)-3'-(2,2-DIMETILPROPIL)-5',6',7',8'-TETRAHIDROESPIRO[CICLOPROPANO-1,9'-[1',2']DIAZA[5',8']METANOCINOLINA], (5'RS,8'SR)-3'-TERT-BUTIL-5',6',7',8'-TETRAHIDROESPIRO[CICLOPROPANO-1,9'-[1',2']DIAZA[5',8']METANOCINOLINA], (5'RS,8'SR)-3'-[(1-METILCICLOPROPIL)METIL]-5',6',7',8'-TETRAHIDROESPIRO[CICLOPROPANO-1,9'-[1',2']DIAZA[5',8']METANOCINOLINA], ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA ENZIMA 11BETA-HIDROESTEROIDE-DESHIDROGENASA-1 (11b-HSD1) Y SON UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS, DIABETES TIPO II, OBESIDAD, HIPERTENSION, DISLIPIDEMIAS, ENTRE OTRAS
PE2011000019A 2008-07-15 2009-07-06 Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes PE20110207A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08160446 2008-07-15

Publications (1)

Publication Number Publication Date
PE20110207A1 true PE20110207A1 (es) 2011-03-31

Family

ID=41050326

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000019A PE20110207A1 (es) 2008-07-15 2009-07-06 Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes

Country Status (17)

Country Link
US (1) US8501940B2 (es)
EP (1) EP2313375A1 (es)
JP (1) JP5575762B2 (es)
KR (1) KR20110036579A (es)
CN (1) CN102089287B (es)
AR (1) AR072803A1 (es)
AU (1) AU2009272895A1 (es)
BR (1) BRPI0915862A2 (es)
CA (1) CA2730059A1 (es)
CL (1) CL2011000061A1 (es)
IL (1) IL209723A0 (es)
MX (1) MX2011000226A (es)
PE (1) PE20110207A1 (es)
RU (1) RU2541533C2 (es)
TW (1) TW201006802A (es)
WO (1) WO2010006940A1 (es)
ZA (1) ZA201009182B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2014055955A1 (en) * 2012-10-05 2014-04-10 Rigel Pharmaceuticals, Inc. Gdf-8 inhibitors
CN105705492B (zh) * 2013-11-05 2019-11-05 豪夫迈·罗氏有限公司 作为rorc调节剂用于治疗自身免疫性疾病的5,6,7,8-四氢-5,8-亚甲基噌啉衍生物
JP6757333B2 (ja) * 2015-05-04 2020-09-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのピリダジン誘導体
JP6757334B2 (ja) * 2015-05-04 2020-09-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＲＯＲｃモジュレーターとしてのピリダジン誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1551878B (zh) * 2001-09-06 2011-08-10 先灵公司 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂
EP1474139B1 (en) * 2002-02-01 2007-11-21 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
BR0307780A (pt) * 2002-02-19 2004-12-28 Ono Pharmaceutical Co Compostos derivados de piridazina fundida e medicamentos contendo os compostos como o ingrediente ativo
CN100374421C (zh) * 2002-11-18 2008-03-12 先灵公司 用于治疗雄激素依赖性疾病的3型17β-羟基类固醇脱氢酶抑制剂
AU2006265201C1 (en) * 2005-07-05 2010-12-09 F. Hoffmann-La Roche Ag Pyridazine derivatives
BRPI0714200A2 (pt) 2006-07-05 2012-12-25 Hoffmann La Roche composto derivado de alquil-piridazina, processo para a sua preparaÇço, composiÇço farmacÊutica que compreende o mesmo, seu uso e mÉtodos para o tratamento e/ou profilaxia de enfermidades

Also Published As

Publication number Publication date
CA2730059A1 (en) 2010-01-21
IL209723A0 (en) 2011-02-28
KR20110036579A (ko) 2011-04-07
ZA201009182B (en) 2011-10-26
JP2011528003A (ja) 2011-11-10
CN102089287A (zh) 2011-06-08
AR072803A1 (es) 2010-09-22
US8501940B2 (en) 2013-08-06
EP2313375A1 (en) 2011-04-27
TW201006802A (en) 2010-02-16
CN102089287B (zh) 2013-10-23
US20100016325A1 (en) 2010-01-21
WO2010006940A1 (en) 2010-01-21
MX2011000226A (es) 2011-02-24
RU2541533C2 (ru) 2015-02-20
RU2011105058A (ru) 2012-08-20
JP5575762B2 (ja) 2014-08-20
AU2009272895A1 (en) 2010-01-21
BRPI0915862A2 (pt) 2015-11-03
CL2011000061A1 (es) 2011-07-01

Similar Documents

Publication Publication Date Title
PE20110207A1 (es) Tetrahidrocinolinas como inhibidores de la 11-beta-hsd1 para la diabetes
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
MY146087A (en) Tricyclic compound, compositions, and methods
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
TN2009000199A1 (en) Heteromonocyclic compound and use thereof
AR111813A2 (es) Compuestos y composiciones para el control de nematodos
MX2010008040A (es) Derivados de pirimidina 5-fluoro como fungicidas.
CO6311079A2 (es) Derivados de aminodihidrotiazina como inhibidores de la enzima bace para el tratamiento de la enfermedad de alzheimer
GEP201706728B (en) Noxious organism control agent
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
SV2010003642A (es) Compuestos
ECSP13012408A (es) Derivados de [1,8]naftiridina
CO6382126A2 (es) Compuestos heteroaromaticos fusionados y espirociclicos para el tratamiento de infecciones bacterianas
CL2012000768A1 (es) Compuestos derivados de acido l-glutamico y l-glutamina marcados con [18f]; procedimiento de preparacion; y su uso para el diagnostico de enfermedades tumorales.
BR112012006180A2 (pt) processos e intermediários para a preparação de análogos de 1'-substituido carba-nucleosídeo
PE20081806A1 (es) Imidazo- y triazolopirimidinas sustituidas
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
EA201290208A1 (ru) Способ лечения андроген-рецептор позитивных раковых заболеваний
CO6260009A2 (es) Derivados de ariloxiacetamida bi-o triciclicos saturados e insaturados y su uso como fungicidas
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
MX2010002899A (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de la histamina-3.
CR20120033A (es) Derivados de 5-fluoro-2-oxopirimidina-1-(2h) carboxilato.
ATE466854T1 (de) 1h-indol-6-ylpiperazin-1-ylmethanonderivate zur verwendung als h3-rezeptormodulatoren

Legal Events

Date Code Title Description
FC Refusal